Objectives

1. Describe the epidemiology and mechanisms contributing to increased cardiovascular disease risk among people with HIV, including the effects of chronic inflammation, immune activation, and aging.
2. Discuss traditional and HIV-specific cardiovascular risk factors that may influence long-term health outcomes in people with HIV.
3. Identify the impact of antiretroviral therapy, comorbid conditions, and social determinants of health on cardiovascular risk management in HIV care.
4. Summarize the results of the REPRIEVE trial on preventing cardiovascular disease in people with HIV.
5. Apply interdisciplinary strategies to optimize cardiovascular risk reduction in people with HIV, including prevention, screening, lifestyle interventions, and pharmacologic management.

Agenda

Welcome/MAAETC Overview 

Speaker Introductions

Presentation 

Q&A

Event Wrap up/ CE Review 

Speaker 

Intended Audience

Physicians, Nurses, Pharmacists, Social Workers, all Healthcare professionals

Contact